<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860870</url>
  </required_header>
  <id_info>
    <org_study_id>CLEN</org_study_id>
    <nct_id>NCT03860870</nct_id>
  </id_info>
  <brief_title>Response to Clenbuterol in Humans</brief_title>
  <official_title>Detectability of Clenbuterol and Physiological Response in Human Skeletal Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the long half-life (~36 hr) of clenbuterol, detection methods such as dried blood&#xD;
      spots (DBS) are a potentially suitable method to easily and non-invasively detect doping&#xD;
      misuse of this compound for several days after ingestion. If, and how long, the compound can&#xD;
      be detected by DBS has not yet been investigated but is of interest due to its potential in&#xD;
      doping-control. The aim is to evaluate whether abuse of clenbuterol can be detected at&#xD;
      relevant concentration levels in samples obtained using DBS and to assess the physiological&#xD;
      response to clenbuterol in skeletal muscle..&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two phases:&#xD;
First phase sequential Second phase crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>First phase - open label Second phase - double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood clenbuterol concentration</measure>
    <time_frame>Before (baseline) as well as 3, 8, 24, 72, 168 and 240 hours after administration of clenbuterol</time_frame>
    <description>Concentration of clenbuterol in dried blood spots</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood clenbuterol concentration</measure>
    <time_frame>Before (baseline) as well as 3, 8, 24, 72, 168 and 240 hours after administration of study drug</time_frame>
    <description>Concentration of clenbuterol in venous blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine clenbuterol concentration</measure>
    <time_frame>Before (baseline) as well as 3, 8, 24, 72, 168 and 240 hours after administration of study drug</time_frame>
    <description>Concentration of clenbuterol in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Before (baseline) and 2.5 hours after administration of study drug</time_frame>
    <description>Maximal voluntary isometric contraction in N/m2 of the quadriceps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle signalling</measure>
    <time_frame>Before (baseline) and 2.5 hours after administration of study drug</time_frame>
    <description>Protein kinase A phosphorylation in vastus lateralis biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma K+</measure>
    <time_frame>Before (baseline) as well as 2.5 hours after administration of study drug</time_frame>
    <description>Venous plasma K+ concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mTOR signalling</measure>
    <time_frame>Before (baseline) as well as 2.5 hours after administration of study drug</time_frame>
    <description>mTOR phosphorylation in vastus lateralis biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic rate</measure>
    <time_frame>Before (baseline) as well as 2.5 hours after administration of study drug</time_frame>
    <description>Respriatory exchange ratio of oxygen and CO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal voluntary strength</measure>
    <time_frame>Before (baseline) and after two-week treatment of study drug</time_frame>
    <description>Maximal voluntary isometric muscle strength of the quadriceps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Before (baseline) and after two-week treatment of study drug</time_frame>
    <description>Lean and fat mass during a DXA-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>Before (baseline) and after two-week treatment of study drug</time_frame>
    <description>Maximal oxygen uptake during maximal exercise</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clenbuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects ingest 80 micrograms of clenbuterol tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects ingest placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenbuterol Oral Product</intervention_name>
    <description>Subjects ingest 4x20 microgram clenbuterol tablets</description>
    <arm_group_label>Clenbuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects ingest placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  18-40 years of age&#xD;
&#xD;
          -  No known contraindications for anabolic drugs (e.g. cancer)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal ECG&#xD;
&#xD;
          -  Steroid abuse&#xD;
&#xD;
          -  Ongoing use of prescription medication&#xD;
&#xD;
          -  heavy resistance training more than 2 times weekly&#xD;
&#xD;
          -  Disease deemed by the MD to infer a risk to participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>August Krogh Building</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Hostrup, PhD</last_name>
      <phone>+4524474785</phone>
      <email>mhostrup@nexs.ku.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dried blood spots</keyword>
  <keyword>skeletal muscle biopsies</keyword>
  <keyword>muscle strength</keyword>
  <keyword>muscle signaling</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clenbuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

